Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.80 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.61 |
| ▸ | CA1 | P00915 | 2/20 | 0.61 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | PPARD | Q03181 | 1/20 | 0.59 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.59 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.59 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6657056 | 1.00 | ACE2 (0.80) | ACE2GPR84CA1FFAR1MAPT | |
| SCHEMBL545070 | 1.00 | ACE2 (0.80) | ACE2GPR84CA1FFAR1MAPT | |
| Dodecane SCHEMBL14691319 | 1.00 | ACE2 (0.80) | ACE2GPR84CA1FFAR1MAPT | |
| SCHEMBL194398 | 1.00 | ACE2 (0.80) | ACE2GPR84CA1FFAR1MAPT | |
| SCHEMBL247871 | 1.00 | ACE2 (0.80) | ACE2GPR84CA1FFAR1MAPT | |
| SCHEMBL22023412 | 1.00 | ACE2 (0.80) | ACE2GPR84CA1FFAR1MAPT | |
| SCHEMBL7080552 | 1.00 | ACE2 (0.80) | ACE2GPR84CA1FFAR1MAPT | |
| SCHEMBL7146627 | 1.00 | ACE2 (0.80) | ACE2GPR84CA1FFAR1MAPT | |
| SCHEMBL2054033 | 1.00 | ACE2 (0.80) | ACE2GPR84CA1FFAR1MAPT | |
| SCHEMBL1115799 | 1.00 | ACE2 (0.80) | ACE2GPR84CA1FFAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1242 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320174-A1 | SPIN ON METAL-ORGANIC FORMULATIONS | MERCK PATENTS GMBH (DE) | 2025-10-16 | — | — | US | claimed |
| CN-117380269-B | Oil-soluble organic molybdenum catalyst and preparation method and application thereof | 北京高新利华科技股份有限公司 | 2024-04-05 | — | — | CN | claimed |
| CN-113423711-B | Thieno [3,2-B ] pyridine derivatives as UDP glycosyltransferase inhibitors and methods of use thereof | 建新公司 | 2024-03-15 | — | — | CN | claimed |
| EP-4334252-A2 | SPIN ON METAL-ORGANIC FORMULATIONS | Merck Patent GmbH (DE) | 2024-03-13 | — | — | EP | claimed |
| CN-117380269-A | Oil-soluble organic molybdenum catalyst and preparation method and application thereof | 北京高新利华科技股份有限公司 | 2024-01-12 | — | — | CN | claimed |
| CN-117295693-A | Spin-on metal-organic formulations | 默克专利股份有限公司 | 2023-12-26 | — | — | CN | claimed |
| CN-116514811-A | Synthesis method of 2, 7-diaza-spiro [3,5] nonane-2-tert-butyl formate | 药璞(上海)医药科技有限公司 | 2023-08-01 | — | — | CN | claimed |
| CN-111533831-B | Method for removing residual metal after hydrogenation of unsaturated polymer | 浙江众立合成材料科技股份有限公司 | 2023-05-30 | — | — | CN | claimed |
| WO-2023081515-A1 | BIODEGRADABLE SUSTAINABLE POLYESTERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-05-11 | — | — | WO | claimed |
| CN-116096719-A | Pyridazinylamino derivatives as ALK5 inhibitors | 奇斯药制品公司 | 2023-05-09 | — | — | CN | claimed |
| US-20050245539-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | US | claimed |
| WO-2005102342-A1 | NEW PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SEXUAL DISORDERS II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | WO | claimed |
| EP-1170343-B1 | INFRARED SENSITIVE COATING LIQUID | ASAHI KASEI CHEMICALS CORP (JP) | 2005-11-02 | — | — | EP | claimed |
| EP-1282368-B1 | AMBIENT STABLE BEVERAGE | UNILEVER PLC (GB) | 2005-07-27 | — | — | EP | claimed |
| WO-2004096810-A1 | 5,7-DIAMINOPYRAZOLO`4,3-D!PYRIMIDINES USEFUL IN THE TREATMENT OF HYPERTENSION | PFIZER LIMITED (GB) | 2004-11-11 | — | — | WO | claimed |
| US-20040044080-A1 | Treatment of dyspareunia with topically administered nitroglycerin formulations | VIVUS, INC. | 2004-03-04 | — | — | US | claimed |
| US-6667285-B1 | Branched-chain carboxylic acid monoalkyl ester with outstanding hydrolytic stability | NEW JAPAN CHEMICAL CO., LTD. (JP) | 2003-12-23 | — | — | US | claimed |
| EP-1225213-A1 | LUBRICATING OIL FOR REFRIGERATOR, HYDRAULIC FLUID COMPOSITION FOR REFRIGERATOR AND METHOD FOR LUBRICATION OF REFRIGERATOR | NEW JAPAN CHEMICAL CO.,LTD. (JP) | 2002-07-24 | — | — | EP | claimed |
| US-6180830-B1 | REDUCING COMPLEX OF RUTHENIUM HAVING ELECTROVALENCY OF-4 AND COORDINATION NUMBER OF 6, WHEREIN AT LEAST ONE LIGAND IS TIN HALIDE, OTHER LIGANDS OPTIONALLY BEING HALOGEN ATOMS | RHODIA CHIMIE (FR) | 2001-01-30 | — | — | US | claimed |
| EP-0874803-B1 | PROCESS FOR PREPARING AMIDO-CARBOXYLIC ACID ESTERS HAVING INTERNAL AMIDE LINKAGES | EASTMAN CHEM CO (US) | 2000-12-27 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320174-A1 | SPIN ON METAL-ORGANIC FORMULATIONS | SLC39A11, SLC39A3, SLC39A7 | ACE2 2841/4885GPR84 4523/4885CA1 2143/4885 |
| US-20040044080-A1 | Treatment of dyspareunia with topically administered nitroglycerin formulations | PDE12, PDE3A, PDE2A | ACE2 1720/4885GPR84 212/4885CA1 3443/4885 |
| US-20050245539-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | FLNB, FLNA, FGB | ACE2 2597/4885GPR84 974/4885CA1 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.